Morgan Lewis Seminars

Life Science and Healthcare Seminar on Cross-Border Transactions & IP Issues | 生命科学与医疗健康领域跨境交易与知识产权法律研讨会

Tuesday, December 5, 2017

Please join Morgan Lewis lawyers for an interactive discussion on best practices for Chinese companies working with life science and healthcare related cross-border transactions and IP issues in the US and China.

Topic will include:

  • Strategies for Chinese companies investing in life science and healthcare technologies and attracting investments in the US and China
  • Strategies for protecting pharmaceuticals, biologicals, and medical devices with exclusivity and patent protection
  • Key terms on cross-border licensing deals on R&D and commercialization of pharmaceutical products
  • Outbound M&A and financing transactions involving Chinese investors


Robert Smyth, Ph.D., advises on biotechnology, pharmaceutical, and chemical patent matters in the United States and around the world. Bob also advises on patent due diligence matters for mergers, acquisitions, public & private offerings, and venture capital financing.  Bob received his B.S. in biology with a concentration in immunology from Syracuse University.  He later received his Ph.D. in pharmacology from Temple University School of Medicine and completed his post-doctoral fellowship in virology at the University of Pennsylvania School of Medicine.  Bob later obtained his J.D. degree from Temple University Beasley School of Law.

Jeffrey G. Killian, Ph.D. helps businesses and inventors secure and enforce patent protection for their inventions and advises on technology aspects of corporate transactions. Jeffrey obtained undergraduate, graduate, and doctoral degrees in materials science and engineering from MIT and Johns Hopkins University, and a J.D. degree from Georgetown University Law Center.  He also served as a nuclear-powered submarine officer in the United States Navy before earning his Ph.D. and J.D.

Shaobin Zhu, with a focus on the technology sector, advises on patent litigation in US district courts and Section 337 investigations at the US International Trade Commission (ITC), as well as client counseling and patent prosecution. Shaobin has helped dozens of Chinese clients successfully resolve their intellectual property disputes in the United States.  Shaobin obtained his LL.B and LL.M degrees from Renmin University of China and a J.D. degree from University of Washington School of Law.  Shaobin also received his M.S. degree in computer science from Iowa State University.

Sabrina He focuses her practice on cross-border mergers and acquisitions, private equity, venture capital and general corporate matters. She also frequently advises emerging biotech and pharmaceutical companies, venture capital and corporate investors on financing and licensing transactions.  Sabrina obtained B.S. in biological science and J.M. degrees from Fudan University and LL.M degree from Columbia Law School.


Please contact Carey Li at



  • 中国公司在美国与中国投资生命科学与医疗健康科技领域以及吸引投资的策略
  • 保护具有独家经营权的药品、生物制品和医疗器械以及专利保护的策略
  • 跨境药物研发及商业化许可交易的主要条款
  • 中国投资人对外跨境并购与股权投资交易


Robert Smyth博士(合伙人)就美国本土与全球的生物技术、制药和化学专利问题提供法律服务。Bob还就合并、收购、公开发行和私募发行以及风险投资等交易提供法律服务。Bob在美国雪城大学获得了生物学学士学位专攻免疫学专业。之后他于美国天普大学医学院获得了药理学博士学位。在宾夕法尼亚大学医学院完成了病毒学博士后研究后,Bob继而在美国天普大学法学院取得法律博士学位。

Jeffrey G. Killian博士(合伙人)帮助企业和发明人对他们的发明进行保护和实行专利保护,并就公司交易的技术方面问题提供法律服务。Jeffrey从麻省理工大学和约翰霍普金斯大学取得材料科学和工程学的本科、硕士以及博士学位,并于乔治城大学法学院取得法律博士学位。在获得理工科博士及法学博士学位之前,Jeffrey在美国海军担任过核动力潜艇军官。




请联系Carey Li(